Meeting
2019 ASCO Annual Meeting
Outcomes of lenalidomide in diffuse large B-cell (DLBCL) and high-grade NHL (HGBCL): A single-center retrospective analysis.
Authors
Thomas David Rodgers
University of Rochester Medical Center, Rochester, NY
Thomas David Rodgers , Andrea M Baran , Patrick Michael Reagan , Carla Casulo , Andrew Evans , Walter Richard Burack , Jonathan W. Friedberg , Paul M. Barr
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Non-Hodgkin Lymphoma
Citation
J Clin Oncol 37, 2019 (suppl; abstr 7547)
DOI
10.1200/JCO.2019.37.15_suppl.7547
Abstract #
7547
Poster Bd #
301
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Outcomes by BCL2 and MYC expression and rearrangements in untreated diffuse large B-cell lymphoma (DLBCL) from the POLARIX trial.
First Author: Franck Morschhauser
Poster
2022 ASCO Annual Meeting
Development and validation of Duoseq as a novel diagnostic and companion assay for lymphoma and other cancers.
First Author: Chrissie Rozzi
Poster
2019 ASCO Annual Meeting
Survival disparities of diffuse large B-cell lymphoma in a community-based cancer center.
First Author: Vinicius Machado Jorge
Poster
2019 ASCO Annual Meeting
Molecular profiling of primary central nervous system lymphoma as compared to activated B-cell subtype of diffuse large B-cell lymphoma.
First Author: Mohamad Barakat